Since several clinical trials have shown that solid tumors are resistant to HDAC inhibitor monotherapy [42], the identified combination therapies could help to increase the therapeutic potential of both HDAC inhibitors and the small molecule inhibitors in chondrosarcoma. The gene discussed is HDAC9; the disease is chondrosarcoma.